Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate functioning as a HER2-targeted topoisomerase I inhibitor, with targeting capability and antitumor activity, employed in research on HER2-positive breast cancer and gastric cancer.

Datopotamab deruxtecan (DS-1062) is an antibody-drug conjugate (ADC) that targets tropomyosin 2 (TROP2) on the surface of trophoblast cells. Datopotamab deruxtecan exhibits antitumor activity by specifically binding to TROP2 and internalizing, releasing DXd to inhibit topoisomerase I (IC₅₀ = 0.31 μM), thereby inducing DNA damage and apoptosis. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) and a HER2-targeted cytotoxic agent, consisting of an anti-HER2 monoclonal antibody conjugated to MMAE via a cleavable linker, used for the treatment of HER2-expressing solid tumors including gastric cancer, breast cancer, and urothelial carcinoma.

Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.

Telisotuzumab vedotin (ABBV-399) is an ADC compound targeting c-Met with antitumor activity, used for research in recurrent squamous cell lung cancer.

Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC).

Enfortumab vedotin-ejfv (Padcev) is an ADC compound targeting Nectin-4 with anti-tumor activity, used in the study of urothelial carcinoma.

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB). Glembatumumab vedotin has potent anticancer effects and can be used in the study of triple negative breast cancer (TNBC).

Clivatuzumab MMAE is an ADC consisting of a humanized monoclonal antibody against MUC1 (mucin) and the anti-mitotic cytotoxin MMAE for pancreatic cancer.

Enapotamab vedotin is an investigational antibody-drug conjugate (ADC) specifically targeting the receptor tyrosine kinase AXL. it consists of a monoclonal antibody linked to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) and demonstrates significant inhibitory potential against high AXL-expressing non-small cell lung cancer (NSCLC), including tumors with resistance to EGFR inhibitors like Osimertinib.

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) that enhances immune cell infiltration and activation within tumors and delays tumor growth. It is used in studies of multiple myeloma.

Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate (ADC) targeting TROP2 (trophoblast cell surface antigen 2), capable of releasing the active payload KL610023 within TROP2-positive tumour cells. an effective topoisomerase I inhibitor that induces DNA damage and leads to cell cycle arrest and apoptosis, for use in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

Tilatamig samrotecan (AZD9592) is an antibody-drug conjugate (ADC) delivering a topoisomerase I (TopoI) inhibitor that targets EGFR and c-MET, inducing DNA double-strand breaks and inhibiting the growth of non-small cell lung cancer cells.

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody–drug conjugate that combines the HER2-targeted antitumor specificity of trastuzumab with the potent cytotoxic activity of the microtubule inhibitor DM1, Trastuzumab emtansine enables selective intracellular delivery of the cytotoxic payload to HER2-expressing cells and supporting translational and mechanistic research in advanced breast cancer models.

ADC Control Human IgG1 kappa-vcMMAE is a human monoclonal antibody and an isotype control for Human IgG1 kappa-vcMMAE that inhibits tubulin polymerization.

Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) targeting HER2. It is composed of a humanized anti-HER2 antibody, a cleavable linker MC-Gly-Gly-Phe-Gly, and an effective payload of the topoisomerase I inhibitor Rezetecán. Trastuzumab rezetecan is utilized in the research of HER2-positive breast cancer.

Rinatabart sesutecan is a highly homogeneous antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). Rinatabart sesutecan consists of a humanized antibody targeting FRα, a hydrophilic cleavable linker, and the topoisomerase I inhibitor exatecan as the payload. It is primarily used for the targeted treatment and mechanistic research of folate receptor-positive solid tumors.

Trastuzumab-MMAE-DXd is an antibody-drug conjugate in which Trastuzumab is conjugated to MMAE as the payload. Trastuzumab is a humanized monoclonal antibody that selectively binds HER2 with high affinity. Trastuzumab has been utilized in research involving HER2-positive metastatic breast cancer and gastric cancer. Trastuzumab-MMAE-DXd serves as a valuable research construct for investigating HER2-targeted delivery systems, antibody-drug conjugate design, and HER2-associated tumor biology.

ABBV-706 is an antibody-drug conjugate (ADC) that targets the receptor tyrosine kinase SEZ6. After binding to the surface of tumor cells, it is internalized and releases a cytotoxic payload, thereby inducing tumor cell death. ABBV-706 is currently in clinical development and has demonstrated potential antitumor activity in solid tumors such as small cell lung cancer.

SGD-1882-Dap-Val is an intermediate used in the synthesis of antibody-drug conjugates (ADCs).

JNJ-89862175 is an antibody-drug conjugate (ADC) that targets ENPP3. JNJ-89862175 specifically recognizes ENPP3 on the surface of tumor cells; after endocytosis and formation of endosomes, the released payload inhibits microtubule polymerization to block mitosis, ultimately inducing tumor cell apoptosis. JNJ-89862175 is intended for use in studies of ENPP3-positive advanced solid tumors.

Pinatuzumab vedotin is an antibody-drug conjugate (ADC) formed by conjugating the humanized anti-CD22 monoclonal antibody pinatuzumab with VcMMAE, and exhibits antitumor activity.

Zilovertamab vedotin is a novel antibody-drug conjugate (ADC) constructed by conjugating the humanized monoclonal antibody zilovertamab with the anti-microtubule cytotoxic drug monomethyl vedotin. It binds to ROR1 on the surface of tumor cells, promotes rapid internalization and trafficking of the complex to lysosomes, followed by ADC cleavage and release of monomethyl vedotin, thereby inducing tumor cell apoptosis. It can be used in cancer-related research.